secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001437749-26-006481
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia reports positive echo results from Phase III HFrEF trial; reduced ventricular remodeling
--------------------------------------------------------------------------------

- CardiAMP cell therapy reduced left ventricular end-diastolic volume (p=0.06) and end-systolic volume (p=0.09).
- In patients with elevated NTproBNP, volume reductions were clinically meaningful and statistically significant (p=0.02, p=0.01).
- Results correlated with reduced major adverse cardiovascular events and improved quality of life.
- Echocardiography outcomes by Yale core lab; data presented at THT 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926006481/0001437749-26-006481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926006481/bcda20260303_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-006481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer